Drug-drug interactions among patients with chronic liver disease: A snapshot by clinical pharmacist

Milica Ćulafić1, Sandra Vezmar Kovačević1, Marina Filipović1, Nikola Gošnjić1, Katarina Vučićević1, Branislava Miljković1, Đorđe Ćulafić2
1Department of Pharmacokinetics and Clinical Pharmacy, Faculty of Pharmacy, University of Belgrade, Serbia
2Clinic of Gastroenterology and Hepatology, Clinical Center of Serbia, Belgrade, Serbia; School of Medicine, University of Belgrade, Serbia

Background

People with chronic liver diseases constitute a group of patients who often join polypharmacy, co-morbidity and pharmacokinetic and pharmacodynamic changes, that cause an increased risk of drug-drug interactions (DDIs).

Objectives

To identify and describe DDIs based on their clinical significance and predictors of their occurrence, among patients with chronic liver diseases. To compare the results from two available electronic sources for interaction evaluation.

Materials and Methods

A study was conducted on a hepatology ward from May to July 2015, at the Gastroenterology and Hepatology Clinic. Data were gathered through a prospective chart review performed by clinical pharmacist during a 4-hour visit once per week. Two separate drug interaction programs (Lexi-Interact and Epocrates) were applied to provide analysis.

Results

Predictors of DDIs
- Total number of drugs per patient
- Number of comorbidities
- Gender

Table 1: Covariates that correlated with the occurrence of DDIs

<table>
<thead>
<tr>
<th>Covariates</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total number of drugs per patient</td>
<td>0.049</td>
</tr>
<tr>
<td>Number of comorbidities</td>
<td>0.023</td>
</tr>
<tr>
<td>Patient age</td>
<td>0.039</td>
</tr>
</tbody>
</table>

Acetylsalicylic acid had the highest risk of causing potentially serious (class D) interactions (25.3%).

Results cont.


From medicines use review of 100 patients with chronic liver diseases we identified:
- 486 DDIs using Lexi-Interact
- 293 using Epocrates data base

The most common type of interaction
- class C and monitor/modify
  - 367 DDIs
  - at least one was found in 83.5% of patients

Conclusions

Most DDIs in the study identified the need for monitoring/modifying therapy. Patients on hydrochlorothiazide, furosemide and bisoprolol were more likely to have DDIs. Lexi-Interact was shown to be more sensitive source. We advocate that on-ward participation of a clinical pharmacist in a Hepatology team may prevent/minimize the frequency and severity of DDIs, provide prompt solutions and enhance patient care.

References


Conflict of interest: none